One Fund Bought Up Henry Schein Stock Amid Record Quarterly Results and a New $200 Million Efficiency Plan

Chicago-based Zuckerman Investment Group increased its Henry Schein stake by 72,040 shares in Q3 (post-trade 281,339 shares valued at $18.67M as of Sept. 30), a roughly $3.38M incremental buy that represents 1.73% of its 13F AUM within a $1.08B U.S. equity portfolio. Henry Schein reported Q3 revenue of $3.3B (+5%), adjusted EBITDA of $295M and non-GAAP EPS of $1.38 (+13% YoY), raised full-year non-GAAP EPS guidance to $4.88–$4.96 and sales growth to 3–4%, and repurchased $229M of stock with $980M remaining authorization; TTM revenue is $12.94B and TTM net income $391M, with the share price at $76.33 (+8% one year).

Analysis

Market structure: Zuckerman’s incremental 72k-share buy is a modest signal of conviction in HSIC’s operational momentum (Q3 sales +5%, tech sales +10%, EPS guide $4.88–4.96). Direct beneficiaries are HSIC stakeholders (shareholders, suppliers of HSIC’s tech services) and secondary beneficiaries include smaller dental-service software vendors that could be consolidated; competitors like McKesson/Cardinal face pressure to match tech-enabled service offerings. The market currently prices HSIC flat vs. peers (1‑yr +8% vs S&P +15.5%), leaving room for re-rating if guidance is delivered.

Risk assessment: Tail risks include a recession-driven pullback in elective dental spend (downside scenario: ~25–35% EPS hit over 12 months), supply-chain shocks raising COGS, or regulatory action on distribution practices. Timewise, 1–4 weeks: muted price move on 13F disclosure; 1–6 months: earnings and buyback cadence are key; 1–3 years: value-creation initiatives targeting >$200m operating improvement drive margin expansion. Hidden dependency: HSIC’s valuation and cash generation depend on dental/practice capex cycles and subscription renewal rates, not obvious from headline revenue growth.

Trade implications: Direct play is a calibrated long in HSIC with defined stops—fundamental upside from buybacks and $200m op‑income plan. Relative trades: long HSIC vs short broad healthcare distributor (MCK) to isolate tech/service re‑rating; options: use 9–12 month call spreads to cap downside while capturing re-rate. Sector rotation: modest overweight to healthcare distribution/health-tech services at expense of commodity-driven pharma distributors; monitor buyback execution and tech-sales growth as re‑rating triggers.

Contrarian angles: Consensus underweights the margin-leverage from $200m operating gains plus ~$980m buyback authorization — if executed, EPS could rise ~10–20% over 12–24 months, implying 15–30% upside vs today. The market may be underpricing HSIC’s tech-driven recurring revenue; conversely, downside is underappreciated if dental capex collapses. Historical parallel: distributor re-ratings post-service expansion (past peers) took 6–18 months, so patience and staging size are critical.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in HSIC over the next 4–8 weeks (entry window $72–$80), target 20–30% upside to $92–$100 within 12–18 months, set stop-loss at ~18% below entry (~$62).
• Implement a pair trade: long HSIC 2% and short MCK 1.5% to isolate HSIC’s tech/service re‑rating; rebalance after each quarterly report (review after Q1/Q2 2026).
• Use options to define risk: buy a 9–12 month HSIC call spread (e.g., buy Jan/Dec 2026 $75 call / sell $95 call) sizing for 0.5–1% portfolio risk to capture re‑rating while limiting downside.
• Increase exposure by another 1–2% only if management announces >$300m in buybacks executed in 12 months or confirms >$150m of realized operating income improvement in next two quarters; reduce exposure if dental-practice ordering falls >10% q/q or organic tech sales decelerate below 3% growth.